Initiate Phase 1b trial of APG777 in asthma
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 3 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 12 May 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“initiating a Phase 1b trial in asthma in the first half of 2025”
What we found
Evidence strength B What the grades mean
Apogee announced first patient dosed in the Phase 1b APG777 asthma trial on May 12, 2025, within the first-half-2025 deadline.
-
B Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777)... in Asthma Confirms trial had been running and reports positive interim results
-
B Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results Announces first patient dosed in Phase 1b APG777 asthma trial
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second checkThe evidence document could not be read for a second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Apogee Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-APGE-000120 · Corrections policy